Listed biotech stocks may have fallen from grace, but large investors’ appetite for life sciences is un-sated. In the last six months, private equity (PE) players have bought or teamed up with three European-based venture capital (VC) firms in a bid to expand their life sciences expertise and holdings – and grab some of the out-sized returns enjoyed by earlier-stage investors over the last few years.
The VCs had open arms, hungry for more capital and fund-raising support as biotech funding rounds, and fund-sizes, swell. “We...
